With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, Monash University and Victorian Heart Hospital, Melbourne, Australia. discusses contributions in the space from therapies with systemwide effects.
With a broad research focus on heart disease risk reduction through the development of novel treatment strategies, Stephen Nicholls, MBBS, PhD, professor of cardiology, Monash University, and director, Victorian Heart Hospital, Melbourne, Australia, discusses contributions in the space from incretin-based therapies glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and tirzepatide, a dual GIP/GLP-1 receptor agonist. The therapies have several systemic effects, including reducing gastric emptying and hemoglobin A1c (HbA1c) and increasing insulin production and release.
Transcript
Can you describe the mechanism of the GIP hormone in promoting weight loss for patients who have tried other treatments and strategies but without success?
I think there's a range of incretin-based therapies, which are being developed for the management of type 2 diabetes, but also for weight loss. Traditionally, these therapies have targeted a factor called GLP-1 receptor, and a number of agents are already in the clinic that target GLP-1. GIP is another incretin-based therapy; it does a number of the same things that GLP does, but it has some complementary functions.
We expect these therapies will reduce food intake, will have some central nervous system effects, which will lead to weight loss. But in addition, you'll see a reduction in gastric emptying; you'll see complimentary effects on the pancreas, including increasing insulin production and release. You also see direct effects on the adipose tissue. And so while some of the effects are the same, there's other effects, which kind of are complementary, and that's why we are seeing, in these early trials, greater weight loss with a dual incretin therapy and better metabolic risk factor control.
Can you discuss the “additive effect” of GIP and GLP-1 that appears to make tirzepatide “greater than the sum of its parts” in helping patients control their A1c and lose weight?
Because we see a little bit more weight loss with tirzepatide compared to your standard GLP-1 receptor agonists, such as dilaglutide and semaglutide, you're going to see a greater improvement in metabolic risk factors. We know that there's a greater reduction in HbA1c. We see a greater proportion of patients with type 2 diabetes having reductions in HbA1c greater than 2%, we're seeing a reduction in C-reactive protein, we're seeing improvement in blood pressure and lipid parameters.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More